» Articles » PMID: 35686293

Clinical Features of Very Early-onset Inflammatory Bowel Disease in Japan: a Retrospective Single-center Study

Overview
Journal Intest Res
Date 2022 Jun 10
PMID 35686293
Authors
Affiliations
Soon will be listed here.
Abstract

Background/aims: Very early-onset inflammatory bowel disease (VEO-IBD), defined as IBD diagnosed in patients younger than 6 years, is a challenge for pediatric gastroenterologists. Although there have been reports regarding VEO-IBD in Western countries, those in Asia are still lacking. This study aimed to investigate the clinical features of Japanese VEO-IBD patients.

Methods: Patients with VEO-IBD diagnosed between 2006 and 2019 were evaluated retrospectively. The disease phenotypes were classified into ulcerative colitis type (UC-type) and Crohn's disease type (CD-type), and the clinical features and courses were compared between the phenotypes.

Results: Overall, 54 VEO-IBD patients (19 patients with UC-type and 35 patients with CD-type) were evaluated. The median age at onset was 18 months. One patient had severe combined immunodeficiency (SCID), and 9 patients had monogenic IBD. Monogenic IBD was more prevalent in the CD-type patients with perianal disease (CD-type (PD)). The age at onset was significantly lower in the CD-type group (P<0.05). The most common initial symptom was bloody stools (70%), followed by diarrhea (63%), weight loss (24%), fever (20%), and perianal disease (20%). Excluding patients with SCID and monogenic IBD, 23 out of 44 patients (52%) required biologics. The biologics were switched in 11 out of 44 patients (25%), and the majority of these patients (82%) were in the CD-type group. Overall, 9 patients (20%) required intestinal resection or ostomy placement.

Conclusions: CD-type tends to occur at an earlier age, and monogenic IBD occurs significantly more frequently in CD-type (PD). Disease severity and treatment should be individualized, owing to the disease heterogeneity.

Citing Articles

Disease phenotypic and outcome of very-early onset inflammatory bowel disease in Asian children: an understudied population.

Lee W, Chew K, Huang J, Tanpowpong P, Mercado K, Reodica A Front Pediatr. 2025; 13:1487253.

PMID: 40051907 PMC: 11882516. DOI: 10.3389/fped.2025.1487253.


Genomic testing identifies monogenic causes in patients with very early-onset inflammatory bowel disease: a multicenter survey in an Iranian cohort.

Eslamian G, Jamee M, Momen T, Rohani P, Ebrahimi S, Mesdaghi M Clin Exp Immunol. 2024; 217(1):1-11.

PMID: 38651248 PMC: 11188541. DOI: 10.1093/cei/uxae037.


Surgical outcomes of very-early-onset ulcerative colitis: retrospective comparative study with older pediatric patients.

Fumita T, Terui K, Shibata R, Takenouchi A, Komatsu S, Oita S Pediatr Surg Int. 2024; 40(1):73.

PMID: 38451357 PMC: 10920427. DOI: 10.1007/s00383-024-05662-8.


Fecal Calprotectin at Postinduction Is Capable of Predicting Persistent Remission and Endoscopic Healing after 1 Year of Treatment with Infliximab in Pediatric Patients with Crohn's Disease.

Lee Y, Kim E, Choi S, Jang H, Kim Y, Choi S Gut Liver. 2023; 18(3):498-508.

PMID: 38013474 PMC: 11096907. DOI: 10.5009/gnl230022.

References
1.
Kerur B, Machan J, Shapiro J, Cerezo C, Markowitz J, Mack D . Biologics Delay Progression of Crohn's Disease, but Not Early Surgery, in Children. Clin Gastroenterol Hepatol. 2018; 16(9):1467-1473. DOI: 10.1016/j.cgh.2018.02.027. View

2.
Aloi M, Lionetti P, Barabino A, Guariso G, Costa S, Fontana M . Phenotype and disease course of early-onset pediatric inflammatory bowel disease. Inflamm Bowel Dis. 2014; 20(4):597-605. DOI: 10.1097/01.MIB.0000442921.77945.09. View

3.
Heyman M, Kirschner B, Gold B, Ferry G, Baldassano R, Cohen S . Children with early-onset inflammatory bowel disease (IBD): analysis of a pediatric IBD consortium registry. J Pediatr. 2005; 146(1):35-40. DOI: 10.1016/j.jpeds.2004.08.043. View

4.
van der Spek J, Groenwold R, van der Burg M, van Montfrans J . TREC Based Newborn Screening for Severe Combined Immunodeficiency Disease: A Systematic Review. J Clin Immunol. 2015; 35(4):416-30. PMC: 4438204. DOI: 10.1007/s10875-015-0152-6. View

5.
Levine A, Griffiths A, Markowitz J, Wilson D, Turner D, Russell R . Pediatric modification of the Montreal classification for inflammatory bowel disease: the Paris classification. Inflamm Bowel Dis. 2011; 17(6):1314-21. DOI: 10.1002/ibd.21493. View